This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. For more details about cookies and how to manage them see our Privacy.
Hope Medicine Announces US FDA Clearance for Phase II Clinical Trial of A First-in-class Monoclonal Antibody, HMI-115, in AGA Alopecia
MORE
Hope Medicine completed US$56 million in Series B financing, strengthening capabilities of global innovation
Hope Medicine announced global license agreement with Bayer AG to advance the development and commercialization of the monoclonal antibody directed against prolactin (PRL) receptor
Follow Us
Top